{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T03:48:10Z","timestamp":1792986490544,"version":"4.5.0"},"reference-count":94,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T00:00:00Z","timestamp":1567641600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["T32 AI 7526-16"],"award-info":[{"award-number":["T32 AI 7526-16"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010470","name":"Gillson Longenbaugh Foundation","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100010470","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Although West Nile virus (WNV) has been a prominent mosquito-transmitted infection in North America for twenty years, no human vaccine has been licensed. With a cumulative number of 24,714 neurological disease cases and 2314 deaths in the U.S. since 1999, plus a large outbreak in Europe in 2018 involving over 2000 human cases in 15 countries, a vaccine is essential to prevent continued morbidity, mortality, and economic burden. Currently, four veterinary vaccines are licensed, and six vaccines have progressed into clinical trials in humans. All four veterinary vaccines require multiple primary doses and annual boosters, but for a human vaccine to be protective and cost effective in the most vulnerable older age population, it is ideal that the vaccine be strongly immunogenic with only a single dose and without subsequent annual boosters. Of six human vaccine candidates, the two live, attenuated vaccines were the only ones that elicited strong immunity after a single dose. As none of these candidates have yet progressed beyond phase II clinical trials, development of new candidate vaccines and improvement of vaccination strategies remains an important area of research.<\/jats:p>","DOI":"10.3390\/v11090823","type":"journal-article","created":{"date-parts":[[2019,9,6]],"date-time":"2019-09-06T02:59:22Z","timestamp":1567738762000},"page":"823","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":90,"title":["Twenty Years of Progress Toward West Nile Virus Vaccine Development"],"prefix":"10.3390","volume":"11","author":[{"given":"Jaclyn A.","family":"Kaiser","sequence":"first","affiliation":[{"name":"Department of Microbiology and Immunology, University of Texas Medical Branch, Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan D.T.","family":"Barrett","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Texas Medical Branch, Galveston, TX 77555, USA"},{"name":"Sealy Institute for Vaccine Sciences, University of Texas Medical Branch, Galveston, TX 77555, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,9,5]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1128\/JVI.72.1.73-83.1998","article-title":"Phylogeny of the Genus Flavivirus","volume":"72","author":"Kuno","year":"1998","journal-title":"J. Virol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"471","DOI":"10.4269\/ajtmh.1940.s1-20.471","article-title":"A neurotropic virus isolated from the blood of a native of uganda","volume":"20","author":"Smithburn","year":"1940","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2015\/376230","article-title":"The global ecology and epidemiology of west nile virus","volume":"2015","author":"Chancey","year":"2015","journal-title":"Biomed Res. Int."},{"key":"ref_4","unstructured":"(2019, July 05). West Nile Virus, Available online: https:\/\/www.cdc.gov\/westnile\/index.html."},{"key":"ref_5","unstructured":"(2019, July 05). West Nile Virus\u2014Symptoms, Diagnosis, & Treatment, Available online: https:\/\/www.cdc.gov\/westnile\/symptoms\/index.html."},{"key":"ref_6","unstructured":"(2019, July 05). West Nile Virus\u2014Statistics and Maps, Available online: https:\/\/www.cdc.gov\/westnile\/statsmaps\/index.html."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"496","DOI":"10.15585\/mmwr.mm6717e1","article-title":"Vital signs: Trends in reported vectorborne disease cases\u2014United States and Territories, 2004\u20132016","volume":"67","author":"Rosenberg","year":"2018","journal-title":"Morb. Mortal. Wkly. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/jtm\/tay096","article-title":"West Nile in Europe: An increasing public health problem","volume":"25","author":"Barrett","year":"2018","journal-title":"J. Travel Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.3390\/ijerph10083543","article-title":"Environmental Drivers of West Nile Fever Epidemiology in Europe and Western Asia\u2014A Review","volume":"10","author":"Paz","year":"2013","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.3201\/eid1410.071396","article-title":"Ecologic Factors Associated with West Nile Virus Transmission, Northeastern United States","volume":"14","author":"Brown","year":"2008","journal-title":"Emerg. Infect. Dis."},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Marcantonio, M., Rizzoli, A., Metz, M., Rosa, R., Marini, G., Chadwick, E., and Neteler, M. (2015). Identifying the Environmental Conditions Favouring West Nile Virus Outbreaks in Europe. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0121158"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1029\/2018GH000161","article-title":"Identifying Environmental Risk Factors and Mapping the Distribution of West Nile Virus in an Endemic Region of North America","volume":"2","author":"Hess","year":"2018","journal-title":"GeoHealth"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1586\/14760584.2015.1083430","article-title":"Current status and future prospects of yellow fever vaccines","volume":"14","author":"Beck","year":"2015","journal-title":"Expert Rev. Vaccines"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1080\/21645515.2015.1022700","article-title":"Serious adverse events associated with yellow fever vaccine","volume":"11","author":"Martins","year":"2015","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"4761","DOI":"10.1128\/JVI.78.9.4761-4775.2004","article-title":"Safety and Efficacy of Chimeric Yellow Fever-Dengue Virus Tetravalent Vaccine Formulations in Nonhuman Primates","volume":"78","author":"Guirakhoo","year":"2004","journal-title":"J. Virol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1093\/trstmh\/try070","article-title":"Implementing a dengue vaccination programme\u2014Who, where and how?","volume":"112","author":"Clapham","year":"2018","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1093\/infdis\/jiv082","article-title":"Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults","volume":"212","author":"Beth","year":"2015","journal-title":"J. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.jcma.2014.12.009","article-title":"Bin Current recommendations for the Japanese encephalitis vaccine","volume":"78","author":"Chen","year":"2015","journal-title":"J. Chin. Med. Assoc."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1099\/0022-1317-76-2-409","article-title":"Molecular basis of attenuation of neurovirulence of wild- type Japanese encephalitis virus strain SA14","volume":"76","author":"Ni","year":"1995","journal-title":"J. Gen. Virol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3635","DOI":"10.1016\/j.vaccine.2010.02.105","article-title":"Phenotypic and genotypic characteristics of Japanese encephalitis attenuated live vaccine virus SA14-14-2 and their stabilities","volume":"28","author":"Yu","year":"2010","journal-title":"Vaccine"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1080\/21645515.2017.1356496","article-title":"Use of the live attenuated Japanese Encephalitis vaccine SA14\u201314\u20132 in children: A review of safety and tolerability studies","volume":"13","author":"Ginsburg","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_22","unstructured":"(2017, July 05). Japanese Encephalitis Virus\u2014Vaccines. Available online: https:\/\/www.who.int\/ith\/vaccines\/japanese_encephalitis\/en\/."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1586\/14760584.2016.1123097","article-title":"Safety and immunogenicity of a live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV\u00ae) in children","volume":"15","author":"Chokephaibulkit","year":"2016","journal-title":"Expert Rev. Vaccines"},{"key":"ref_24","first-page":"23","article-title":"Homology among Eleven Flavivirus by Comparative Nucleotide Sequence of Geomic RNAs and Deduced Amino Acid Sequences of Viral Proteins","volume":"33","author":"Tanaka","year":"1991","journal-title":"Trop. Med."},{"key":"ref_25","first-page":"221","article-title":"Equine vaccine for West Nile virus","volume":"114","author":"Ng","year":"2003","journal-title":"Dev. Biol."},{"key":"ref_26","unstructured":"(2019, July 05). Vetera WNV. Available online: https:\/\/www.bi-vetmedica.com\/species\/equine\/products\/vetera_vaccines\/Vetera_WNV.html."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.vetimm.2008.02.002","article-title":"A West Nile virus (WNV) recombinant canarypox virus vaccine elicits WNV-specific neutralizing antibodies and cell-mediated immune responses in the horse","volume":"123","author":"Minke","year":"2008","journal-title":"Vet. Immunol. Immunopathol."},{"key":"ref_28","unstructured":"(2019, July 16). Prestige WNV. Available online: https:\/\/merckusa.cvpservice.com\/product\/basic\/view\/1047544."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.2460\/javma.2004.225.1084","article-title":"Evaluation of an outbreak of West Nile virus infection in horses: 569 cases (2002)","volume":"225","author":"Schuler","year":"2004","journal-title":"J. Am. Vet. Med. Assoc."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1051\/vetres:2006045","article-title":"Incidence and effects of West Nile virus infection in vaccinated and unvaccinated horses in California","volume":"38","author":"Gardner","year":"2007","journal-title":"Vet. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.vetmic.2013.08.013","article-title":"West Nile viral infection of equids","volume":"167","author":"Angenvoort","year":"2013","journal-title":"Vet. Microbiol."},{"key":"ref_32","first-page":"165","article-title":"The safety and use of canarypox vectored vaccines","volume":"84","author":"Plotkin","year":"1995","journal-title":"Dev. Biol. Stand."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1111\/j.1469-0691.2012.03944.x","article-title":"Vaccines for the elderly","volume":"18","author":"Weinberger","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"64","DOI":"10.2174\/1876326X01206010064","article-title":"Balancing the Efficacy and Safety of Vaccines in the Elderly","volume":"6","author":"Amanna","year":"2013","journal-title":"Open Longev. Sci."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/S0264-410X(00)00038-4","article-title":"Points to consider in the development of a surrogate for efficacy of novel Japanese encephalitis virus vaccines","volume":"18","author":"Markoff","year":"2000","journal-title":"Vaccine"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1016\/j.vaccine.2005.07.002","article-title":"Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2-3 September, 2004","volume":"23","author":"Hombach","year":"2005","journal-title":"Vaccine"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"12941","DOI":"10.1128\/JVI.77.24.12941-12949.2003","article-title":"Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice","volume":"77","author":"Engle","year":"2003","journal-title":"J. Virol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"8312","DOI":"10.1128\/JVI.78.15.8312-8321.2004","article-title":"Role of CD8+ T cells in control of West Nile virus infection","volume":"78","author":"Shrestha","year":"2004","journal-title":"J. Virol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1084\/jem.20090222","article-title":"Key role of T cell defects in age-related vulnerability to West Nile virus","volume":"206","author":"Brien","year":"2009","journal-title":"J. Exp. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1016\/j.vaccine.2008.02.009","article-title":"The relative contribution of antibody and CD8+ T cells to vaccine immunity against West Nile encephalitis virus","volume":"26","author":"Shrestha","year":"2008","journal-title":"Vaccine"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3882","DOI":"10.4049\/jimmunol.1002799","article-title":"Repeated in vivo stimulation of T and B cell responses in old mice generates protective immunity against lethal West Nile virus encephalitis","volume":"186","author":"Uhrlaub","year":"2011","journal-title":"J. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/infdis\/jiy623","article-title":"Immune Correlates of Protection from West Nile Virus Neuroinvasion and Disease","volume":"219","author":"Graham","year":"2019","journal-title":"J. Infect. Dis."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1093\/infdis\/jiq074","article-title":"Development of antigen-specific memory CD8+ T cells following live-attenuated chimeric West Nile virus vaccination","volume":"203","author":"Smith","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_44","unstructured":"(2019, August 15). Correlates of Vaccine-Induced Protection: Methods and Implications. Available online: https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/84288\/WHO_IVB_13.01_eng.pdf;sequence=1."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/j.vaccine.2008.01.021","article-title":"A 5-year follow-up of antibody response in children vaccinated with single dose of live attenuated SA14-14-2 Japanese encephalitis vaccine: Immunogenicity and anamnestic responses","volume":"26","author":"Sohn","year":"2008","journal-title":"Vaccine"},{"key":"ref_46","unstructured":"(2019, July 05). Yellow Fever Vaccine, Available online: https:\/\/www.cdc.gov\/yellowfever\/vaccine\/index.html."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"5197","DOI":"10.1016\/j.vaccine.2010.05.069","article-title":"Long-term immunity and immune response to a booster dose following vaccination with the inactivated Japanese encephalitis vaccine IXIARO\u00ae, IC51","volume":"28","author":"Eder","year":"2010","journal-title":"Vaccine"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"tav020","DOI":"10.1093\/jtm\/tav020","article-title":"Analysis of delayed TBE-vaccine booster after primary vaccination","volume":"23","author":"Aerssens","year":"2016","journal-title":"J. Travel Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.biologicals.2019.06.001","article-title":"Evaluation of environment safety of a Japanese encephalitis live attenuated vaccine","volume":"60","author":"Liu","year":"2019","journal-title":"Biologicals"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"480","DOI":"10.4269\/ajtmh.2000.62.480","article-title":"Growth Characteristics of the Chimeric Japanese Encephalitis Virus Vaccine Candidate, ChimeriVax-JE (YF\/JE SA14-14-2), in Culex Tritaeniorhychus, Aedes Albopictus, and Aedes Aegypti Mosquitoes","volume":"62","author":"Bhatt","year":"2000","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Danet, L., Beauclair, G., Berthet, M., Moratorio, G., Gracias, S., Tangy, F., Choumet, V., and Jouvenet, N. (2019). Midgut barriers prevent the replication and dissemination of the yellow fever vaccine in Aedes aegypti. PLoS Negl. Trop. Dis., 13.","DOI":"10.1101\/577213"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6802a1","article-title":"Japanese encephalitis vaccine: Recommendations of the Advisory Committee on Immunization Practices","volume":"68","author":"Hills","year":"2019","journal-title":"MMWR Recomm. Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"524","DOI":"10.4269\/ajtmh.1973.22.524","article-title":"Passive immunity for arbovirus infection: I. Artificially Induced Prophylaxis in man and mouse for Japanese (B) encephalitis","volume":"22","author":"Hammon","year":"1973","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"535","DOI":"10.4269\/ajtmh.1973.22.535","article-title":"Passive immunity for arbovirus infection. II. Quantitative aspects of naturally and artificially acquired protection in mice for Japanese (B) encephalitis virus","volume":"22","author":"Lubiniecki","year":"1973","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"5527","DOI":"10.1128\/JVI.73.7.5527-5534.1999","article-title":"The anamnestic neutralizing antibody response is critical for protection of mice from challenge following vaccination with a plasmid encoding the Japanese encephalitis virus premembrane and envelope genes","volume":"73","author":"Konishi","year":"1999","journal-title":"J. Virol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1016\/j.vaccine.2004.03.027","article-title":"Protection against Japanese encephalitis virus strains representing four genotypes by passive transfer of sera raised against ChimeriVaxTM-JE experimental vaccine","volume":"22","author":"Beasley","year":"2004","journal-title":"Vaccine"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"5925","DOI":"10.1016\/j.vaccine.2011.06.062","article-title":"Correlation of protection against Japanese encephalitis virus and JE vaccine (IXIARO \u00ae) induced neutralizing antibody titers","volume":"29","author":"Klade","year":"2011","journal-title":"Vaccine"},{"key":"ref_58","unstructured":"(2019, July 30). Recommendations for Japanese Encephalitis Vaccine (Inactivated) for Human Use (Revised 2007). Available online: https:\/\/www.who.int\/biologicals\/vaccines\/Annex_1_WHO_TRS_963.pdf?ua=1."},{"key":"ref_59","unstructured":"(2019, July 30). Recommendations to Assure the Quality, Safety and Efficacy of Japanese Encephalitis Vaccines (live, attenuated) for human use. Available online: https:\/\/www.who.int\/biologicals\/vaccines\/JE-Recommendations_TRS_980_Annex_7.pdf?ua=1."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1177\/0300985810372507","article-title":"Flavivirus encephalitis: Pathological aspects of mouse and other animal models","volume":"47","author":"Kimura","year":"2010","journal-title":"Vet. Pathol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"955","DOI":"10.4269\/ajtmh.2008.79.955","article-title":"Evaluation of the Efficacy of a Recombinant Subunit West Nile Vaccine in Syrian Golden Hamsters","volume":"79","author":"Siirin","year":"2008","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"714","DOI":"10.3201\/eid0704.017420","article-title":"West Nile virus infection in the golden hamster (Mesocricetus auratus): A model for west Nile encephalitis","volume":"7","author":"Xiao","year":"2001","journal-title":"Emerg. Infect. Dis."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1086\/431153","article-title":"Persistent West Nile Virus Infection in the Golden Hamster: Studies on Its Mechanism and Possible Implications for Other Flavivirus Infections","volume":"192","author":"Tesh","year":"2005","journal-title":"J. Infect. Dis."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"12497","DOI":"10.1128\/JVI.78.22.12497-12507.2004","article-title":"ChimeriVax-West Nile Virus Live-Attenuated Vaccine: Preclinical Evaluation of Safety, Immunogenicity, and Efficacy","volume":"78","author":"Arroyo","year":"2004","journal-title":"J. Virol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1128\/CVI.00119-09","article-title":"Immunogenicity and protective efficacy of a recombinant subunit West Nile Virus vaccine in rhesus monkeys","volume":"16","author":"Lieberman","year":"2009","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"6392","DOI":"10.1016\/j.vaccine.2006.06.008","article-title":"Chimeric West Nile\/dengue virus vaccine candidate: Preclinical evaluation in mice, geese and monkeys for safety and immunogenicity","volume":"24","author":"Pletnev","year":"2006","journal-title":"Vaccine"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.vaccine.2016.11.080","article-title":"Pre-clinical development of a hydrogen peroxide-inactivated West Nile virus vaccine","volume":"35","author":"Poore","year":"2017","journal-title":"Vaccine"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.3390\/v5102384","article-title":"Vaccines in Development against West Nile Virus","volume":"5","author":"Brandler","year":"2013","journal-title":"Viruses"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.3390\/ijerph10094200","article-title":"A Review of Vaccine Approaches for West Nile Virus","volume":"10","author":"Iyer","year":"2013","journal-title":"Int. J. Environ. Res. Public Health"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1586\/14760584.2014.906309","article-title":"Current Trends in West Nile Virus Vaccine Development","volume":"13","author":"Amanna","year":"2014","journal-title":"Expert Rev. Vaccines"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1016\/j.vaccine.2016.02.042","article-title":"Immunogenicity and protective efficacy of recombinant Modified Vaccinia virus Ankara candidate vaccines delivering West Nile virus envelope antigens","volume":"34","author":"Volz","year":"2016","journal-title":"Vaccine"},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Li, N., Zhang, Y.-N., Deng, C.-L., Shi, P.-Y., Yuan, Z.-M., and Zhang, B. (2019). Replication-defective West Nile virus with NS1 deletion as a new vaccine platform for flavivirus. J. Virol., 93.","DOI":"10.1128\/JVI.00720-19"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Van Hoeven, N., Joshi, S.W., Nana, G.I., Bosco, A., Fox, C., Bowen, R.A., Clements, D.E., Martyak, T., Parks, E., and Baldwin, S. (2016). A Novel Synthetic TLR-4 Agonist Adjuvant Increases the Protective Response to a Clinical-Stage West Nile Virus Vaccine Antigen in Multiple Formulations. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0149610"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.4049\/jimmunol.178.5.2699","article-title":"Immunization of Flavivirus West Nile Recombinant Envelope Domain III Protein Induced Specific Immune Response and Protection against West Nile Virus Infection","volume":"178","author":"Chu","year":"2007","journal-title":"J. Immunol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1128\/JVI.01886-10","article-title":"Immunodominance and Functional Activities of Antibody Responses to Inactivated West Nile Virus and Recombinant Subunit Vaccines in Mice","volume":"85","author":"Zlatkovic","year":"2011","journal-title":"J. Virol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"5479","DOI":"10.1016\/j.vaccine.2016.09.044","article-title":"Supramolecular peptide hydrogel adjuvanted subunit vaccine elicits protective antibody responses against West Nile virus","volume":"34","author":"Friedrich","year":"2016","journal-title":"Vaccine"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1086\/523650","article-title":"A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial","volume":"196","author":"Martin","year":"2007","journal-title":"J. Infect. Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1093\/infdis\/jir054","article-title":"A West Nile Virus DNA Vaccine Utilizing a Modified Promoter Induces Neutralizing Antibody in Younger and Older Healthy Adults in a Phase I Clinical Trial","volume":"203","author":"Ledgerwood","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_79","unstructured":"Coller, I.B., Pai, V., Weeks-levy, C.L., and Ogata, S.A. (2017). Recombinant Subunit West Nile Virus Vaccine for Protection of Human Subjects. (0165349 A1), U.S. Patent."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"5772","DOI":"10.1016\/j.vaccine.2013.07.064","article-title":"The live attenuated chimeric vaccine rWN\/DEN4 30 is well-tolerated and immunogenic in healthy flavivirus-na\u00efve adult volunteers","volume":"31","author":"Durbin","year":"2013","journal-title":"Vaccine"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1093\/infdis\/jiw501","article-title":"A Live Attenuated Chimeric West Nile Virus Vaccine, rWN\/DEN4\u039430, Is Well Tolerated and Immunogenic in Flavivirus-Naive Older Adult Volunteers","volume":"215","author":"Pierce","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1016\/j.vaccine.2018.12.026","article-title":"An observer blinded, randomized, placebo-controlled, phase I dose escalation trial to evaluate the safety and immunogenicity of an inactivated West Nile virus Vaccine, HydroVax-001, in healthy adults","volume":"37","author":"Woods","year":"2019","journal-title":"Vaccine"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"4214","DOI":"10.1016\/j.vaccine.2018.12.020","article-title":"Advanced oxidation technology for the development of a next-generation inactivated West Nile virus vaccine","volume":"37","author":"Quintel","year":"2019","journal-title":"Vaccine"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1080\/14760584.2017.1357471","article-title":"Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases","volume":"16","author":"Barrett","year":"2017","journal-title":"Expert Rev. Vaccines"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"3318","DOI":"10.1016\/j.vaccine.2010.02.092","article-title":"An inactivated West Nile Virus vaccine derived from a chemically synthesized cDNA system","volume":"28","author":"Orlinger","year":"2010","journal-title":"Vaccine"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"6694","DOI":"10.1073\/pnas.0601932103","article-title":"A live, attenuated recombinant West Nile virus vaccine","volume":"103","author":"Monath","year":"2006","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1093\/infdis\/jiq003","article-title":"Phase II, randomized, double-blind, placebo-controlled, multicenter study to investigate the immunogenicity and safety of a West Nile virus vaccine in healthy adults","volume":"203","author":"Biedenbender","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1016\/j.vaccine.2012.08.063","article-title":"Phase II, dose ranging study of the safety and immunogenicity of single dose West Nile vaccine in healthy adults \u2265 50 years of age","volume":"30","author":"Dayan","year":"2012","journal-title":"Vaccine"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1093\/infdis\/jiy179","article-title":"Mosquito Saliva. The Hope for a Universal Arbovirus Vaccine?","volume":"20852","author":"Manning","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_90","unstructured":"(2019, July 03). Study in Healthy Volunteers to Evaluate the Safety and Immunogenicity of AGS-v, a Universal Mosquito-Borne Disease Vaccine, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT03055000."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1056\/NEJM198809083191004","article-title":"Protection against Japanese Encephalitis by Inactivated Vaccines","volume":"319","author":"Hoke","year":"1988","journal-title":"N. Engl. J. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"402","DOI":"10.4269\/ajtmh.13-0206","article-title":"Initial and Long-Term Costs of Patients Hospitalized with West Nile Virus Disease","volume":"90","author":"Staples","year":"2014","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1016\/j.vaccine.2016.11.078","article-title":"Cost effectiveness of a targeted age-based West Nile virus vaccination program","volume":"35","author":"Shankar","year":"2017","journal-title":"Vaccine"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines-a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/11\/9\/823\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:16:59Z","timestamp":1760188619000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/11\/9\/823"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,5]]},"references-count":94,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,9]]}},"alternative-id":["v11090823"],"URL":"https:\/\/doi.org\/10.3390\/v11090823","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,5]]}}}